GlassScriptPhysician profile
Mark Craton Hutto
NPI 1699844159
$11,546.80
in general payments reported to CMS, 2019-2025
25 companies · $4,818 in 2025
The $4,818 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,239 · 2020: $772 · 2021: $2,104 · 2022: $805 · 2023: $502 · 2024: $306 · 2025: $4,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,575 · Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,575.00 |
| Food and Beverage | $1,051.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $4,575.00 | 2025 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $1,012.94 | 2019-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $804.49 | 2019-2025 | Abilify Asimtufii |
| Alkermes, INC. | $737.99 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $571.18 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $566.31 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $559.64 | 2019-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $482.80 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $417.64 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $298.47 | 2019-2025 | Uzedy |
| Allergan, INC. | $273.88 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $173.36 | 2021-2025 | Ingrezza |
| Indivior INC. | $130.40 | 2021-2024 | Perseris |
| Astrazeneca Pharmaceuticals LP | $124.93 | 2021 | |
| Bausch Health US, LLC | $123.72 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $121.28 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $113.15 | 2024-2025 | Cobenfy |
| Eisai INC. | $112.63 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $112.43 | 2019-2022 | |
| Shire North American Group INC | $79.27 | 2019 | |
| Corium, LLC | $75.78 | 2021-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $34.24 | 2022 | |
| Avanir Pharmaceuticals, INC. | $19.63 | 2019 | |
| Adlon Therapeutics L.P. | $13.29 | 2019 | |
| Noven Therapeutics, LLC | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hutto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.